SLC5A2 and hydrops fetalis: These pharmacological prognosis-modifying treatments, however, included neither SGLT2 inhibitors (which were lacking FDA or EMA approval for HF treatment by the end of study recruitment in March 2018) nor cardiac glycosides (which were an exclusion criterion to our study for also lowering HR), both currently recommended in ESC HF guidelines (class of recommendation I and II, respectively) [8].